Abstract
Hypoactive sexual desire disorder (HSDD) is a common multifactorial condition which is characterized by a decrease in sexual desire that causes marked personal distress and/ or interpersonal difficulty. The general idea that HSDD is a sexual dysfunction difficult to treat is due to the large number of potential causes and contributing factors. Indeed, a balanced approach comprising both biological and psycho-relational factors is mandatory for accurate diagnosis and tailored management in clinical practice. There are currently no approved pharmacological treatments for premenopausal women with HSDD, while transdermal testosterone is approved in Europe for postmenopausal women who experience HSDD as a result of a bilateral oophorectomy. Even though the role of sex hormones in modulating the sexual response during the entire reproductive life span of women is crucial, a better understanding of the neurobiological basis of sexual desire supports the idea that selective psychoactive agents may be proposed as nonhormonal treatments to restore the balance between excitatory and inhibitory stimuli leading to a normal sexual response cycle. We conclude that the ideal clinical approach to HSDD remains to be established in term of efficacy and safety, and further research is needed to develop specific hormonal and nonhormonal pharmacotherapies for individualized care in women.
| Original language | English |
|---|---|
| Pages (from-to) | 167-175 |
| Number of pages | 9 |
| Journal | International Journal of Women's Health |
| Volume | 2 |
| Issue number | 1 |
| Publication status | Published - 2010 |
Fingerprint
Keywords
- Distress
- Psychoactive drugs
- Psychosexual interventions
- Sexual desire
- Testosterone
ASJC Scopus subject areas
- Obstetrics and Gynaecology
- Oncology
- Maternity and Midwifery
Cite this
Management of hypoactive sexual desire disorder in women : Current and emerging therapies. / Nappi, Rossella E.; Martini, Ellis; Terreno, Erica; Albani, Francesca; Santamaria, Valentina; Tonani, Silvia; Chiovato, Luca; Polatti, Franco.
In: International Journal of Women's Health, Vol. 2, No. 1, 2010, p. 167-175.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Management of hypoactive sexual desire disorder in women
T2 - Current and emerging therapies
AU - Nappi, Rossella E.
AU - Martini, Ellis
AU - Terreno, Erica
AU - Albani, Francesca
AU - Santamaria, Valentina
AU - Tonani, Silvia
AU - Chiovato, Luca
AU - Polatti, Franco
PY - 2010
Y1 - 2010
N2 - Hypoactive sexual desire disorder (HSDD) is a common multifactorial condition which is characterized by a decrease in sexual desire that causes marked personal distress and/ or interpersonal difficulty. The general idea that HSDD is a sexual dysfunction difficult to treat is due to the large number of potential causes and contributing factors. Indeed, a balanced approach comprising both biological and psycho-relational factors is mandatory for accurate diagnosis and tailored management in clinical practice. There are currently no approved pharmacological treatments for premenopausal women with HSDD, while transdermal testosterone is approved in Europe for postmenopausal women who experience HSDD as a result of a bilateral oophorectomy. Even though the role of sex hormones in modulating the sexual response during the entire reproductive life span of women is crucial, a better understanding of the neurobiological basis of sexual desire supports the idea that selective psychoactive agents may be proposed as nonhormonal treatments to restore the balance between excitatory and inhibitory stimuli leading to a normal sexual response cycle. We conclude that the ideal clinical approach to HSDD remains to be established in term of efficacy and safety, and further research is needed to develop specific hormonal and nonhormonal pharmacotherapies for individualized care in women.
AB - Hypoactive sexual desire disorder (HSDD) is a common multifactorial condition which is characterized by a decrease in sexual desire that causes marked personal distress and/ or interpersonal difficulty. The general idea that HSDD is a sexual dysfunction difficult to treat is due to the large number of potential causes and contributing factors. Indeed, a balanced approach comprising both biological and psycho-relational factors is mandatory for accurate diagnosis and tailored management in clinical practice. There are currently no approved pharmacological treatments for premenopausal women with HSDD, while transdermal testosterone is approved in Europe for postmenopausal women who experience HSDD as a result of a bilateral oophorectomy. Even though the role of sex hormones in modulating the sexual response during the entire reproductive life span of women is crucial, a better understanding of the neurobiological basis of sexual desire supports the idea that selective psychoactive agents may be proposed as nonhormonal treatments to restore the balance between excitatory and inhibitory stimuli leading to a normal sexual response cycle. We conclude that the ideal clinical approach to HSDD remains to be established in term of efficacy and safety, and further research is needed to develop specific hormonal and nonhormonal pharmacotherapies for individualized care in women.
KW - Distress
KW - Psychoactive drugs
KW - Psychosexual interventions
KW - Sexual desire
KW - Testosterone
UR - http://www.scopus.com/inward/record.url?scp=77955536114&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955536114&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:77955536114
VL - 2
SP - 167
EP - 175
JO - International Journal of Women's Health
JF - International Journal of Women's Health
SN - 1179-1411
IS - 1
ER -